{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T01:04:57Z","timestamp":1789520697803,"version":"build-2803163510"},"reference-count":98,"publisher":"IMR Press","issue":"4","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"VA Merit","award":["VA1 I01 BX006280-02"],"award-info":[{"award-number":["VA1 I01 BX006280-02"]}]},{"name":"VA RCS","award":["1IK6BX007114"],"award-info":[{"award-number":["1IK6BX007114"]}]},{"name":"NIH","award":["RO1 CA266970"],"award-info":[{"award-number":["RO1 CA266970"]}]},{"name":"NIH","award":["R01 CA267893"],"award-info":[{"award-number":["R01 CA267893"]}]},{"name":"MCC Pilot","award":["CCSG P30 CA054174"],"award-info":[{"award-number":["CCSG P30 CA054174"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Front. Biosci. (Landmark Ed)"],"abstract":"<jats:p>Ferroptosis is a regulated form of cell death driven by iron-dependent lipid peroxidation and insufficient antioxidant defenses and is mechanistically distinct from apoptosis, necroptosis, and other cell death mechanisms. Over the past decade, ferroptosis has emerged as a significant determinant of cancer cell fate. An increasing body of research indicates that it may serve as a vulnerability in breast cancer treatment. Breast cancers undergo significant metabolic and redox reprogramming that directly influences ferroptosis regulation, including alterations in iron homeostasis, polyunsaturated lipid metabolism, and antioxidant networks. Sensitivity to ferroptosis varies among breast cancer subtypes, underscoring subtype-specific metabolic requirements and stress-response mechanisms. Ferroptosis plays a critical role in breast cancer stem cells (BCSCs), therapeutic resistance, and tumor recurrence. Targeting ferroptosis provides a promising therapeutic strategy to eradicate drug-resistant, stem-like populations. Ferroptosis also profoundly influences the tumor microenvironment (TME) by altering immune cell function, reshaping stromal cell interactions, and modulating cellular responses to hypoxia and metabolic stress. This review summarizes the current mechanistic insights into ferroptosis regulation in breast cancer and discusses therapeutic avenues targeting breast cancer cells, stem cells, and the tumor microenvironment. Understanding ferroptosis mechanisms in breast cancer subtypes may enable rational, biomarker-guided strategies to overcome therapeutic resistance and improve clinical outcomes for patients with breast cancer.<\/jats:p>","DOI":"10.31083\/fbl50950","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T09:29:27Z","timestamp":1777454967000},"source":"Crossref","is-referenced-by-count":3,"title":["Ferroptosis in Breast Cancer: Molecular Insights and Therapeutic Strategies"],"prefix":"10.31083","volume":"31","author":[{"given":"Nahid","family":"Iftikhar","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Texas Health San Antonio, San Antonio, TX 78229, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7381-6962","authenticated-orcid":true,"given":"Suryavathi","family":"Viswanadhapalli","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Texas Health San Antonio, San Antonio, TX 78229, USA"},{"name":"Mays Cancer Center, University of Texas Health San Antonio, San Antonio, TX 78229, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uday P.","family":"Pratap","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Texas Health San Antonio, San Antonio, TX 78229, USA"},{"name":"Mays Cancer Center, University of Texas Health San Antonio, San Antonio, TX 78229, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2849-4076","authenticated-orcid":true,"given":"Ratna K.","family":"Vadlamudi","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Texas Health San Antonio, San Antonio, TX 78229, USA"},{"name":"Mays Cancer Center, University of Texas Health San Antonio, San Antonio, TX 78229, USA"},{"name":"Audie L. Murphy Division, South Texas Veterans Health Care System, San Antonio, TX 78229, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians. 2021; 71: 209\u2013249.","DOI":"10.3322\/caac.21660"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Perou CM, S\u00f8rlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000; 406: 747\u2013752.","DOI":"10.1038\/35021093"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Goldhirsch A, Wood WC, Coates AS, Gelber RD, Th\u00fcrlimann B, Senn HJ, et al. Strategies for subtypes\u2013dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Annals of Oncology. 2011; 22: 1736\u20131747.","DOI":"10.1093\/annonc\/mdr304"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Denkert C, Rachakonda S, Karn T, Weber K, Martin M, Marm\u00e9 F, et al. Dynamics of molecular heterogeneity in high-risk luminal breast cancer-From intrinsic to adaptive subtyping. Cancer Cell. 2025; 43: 232\u2013247.e4.","DOI":"10.1016\/j.ccell.2025.01.002"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. The New England Journal of Medicine. 2010; 363: 1938\u20131948.","DOI":"10.1056\/NEJMra1001389"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Lowe L, LaValley JW, Felsher DW. Tackling heterogeneity in treatment-resistant breast cancer using a broad-spectrum therapeutic approach. Cancer Drug Resistance. 2022; 5: 917\u2013925.","DOI":"10.20517\/cdr.2022.40"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Baliu-Piqu\u00e9 M, Pandiella A, Ocana A. Breast Cancer Heterogeneity and Response to Novel Therapeutics. Cancers. 2020; 12: 3271.","DOI":"10.3390\/cancers12113271"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012; 149: 1060\u20131072.","DOI":"10.1016\/j.cell.2012.03.042"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Zhou J, Yang W, Tang H, Zou Y, Zhou Z, Peng C, et al. Co-targeting ferroptosis and immune evasion through small molecules in breast cancer. Journal of Translational Internal Medicine. 2025; 13: 516\u2013536.","DOI":"10.1515\/jtim-2025-0093"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. Nature Reviews. Molecular Cell Biology. 2021; 22: 266\u2013282.","DOI":"10.1038\/s41580-020-00324-8"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Liu Y, Hu Y, Jiang Y, Bu J, Gu X. Targeting ferroptosis, the achilles\u2019 heel of breast cancer: A review. Frontiers in Pharmacology. 2022; 13: 1036140.","DOI":"10.3389\/fphar.2022.1036140"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Ge A, He Q, Zhao D, Li Y, Chen J, Deng Y, et al. Mechanism of ferroptosis in breast cancer and research progress of natural compounds regulating ferroptosis. Journal of Cellular and Molecular Medicine. 2024; 28: e18044.","DOI":"10.1111\/jcmm.18044"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Hu K, Qiu J, Hu Y, Wang Y, Yu C, Wu Y. Efficacy of FERscore in predicting sensitivity to ferroptosis inducers in breast cancer. NPJ Breast Cancer. 2024; 10: 74.","DOI":"10.1038\/s41523-024-00685-9"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Wu M, Zhang X, Zhang W, Chiou YS, Qian W, Liu X, et al. Cancer stem cell regulated phenotypic plasticity protects metastasized cancer cells from ferroptosis. Nature Communications. 2022; 13: 1371.","DOI":"10.1038\/s41467-022-29018-9"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Sies H. Oxidative stress: a concept in redox biology and medicine. Redox Biology. 2015; 4: 180\u2013183.","DOI":"10.1016\/j.redox.2015.01.002"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Jakubiak GK, Osadnik K, Lejawa M, Osadnik T, Go\u0142awski M, Lewandowski P, et al. \u201cObesity and Insulin Resistance\u201d Is the Component of the Metabolic Syndrome Most Strongly Associated with Oxidative Stress. Antioxidants. 2021; 11: 79.","DOI":"10.3390\/antiox11010079"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Jakubiak GK, Osadnik K, Lejawa M, Kasperczyk S, Osadnik T, Pawlas N. Oxidative Stress in Association with Metabolic Health and Obesity in Young Adults. Oxidative Medicine and Cellular Longevity. 2021; 2021: 9987352.","DOI":"10.1155\/2021\/9987352"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Hayes JD, Dinkova-Kostova AT, Tew KD. Oxidative Stress in Cancer. Cancer Cell. 2020; 38: 167\u2013197.","DOI":"10.1016\/j.ccell.2020.06.001"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Endale HT, Tesfaye W, Mengstie TA. ROS induced lipid peroxidation and their role in ferroptosis. Frontiers in Cell and Developmental Biology. 2023; 11: 1226044.","DOI":"10.3389\/fcell.2023.1226044"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Yu Y, Yan Y, Niu F, Wang Y, Chen X, Su G, et al. Ferroptosis: a cell death connecting oxidative stress, inflammation and cardiovascular diseases. Cell Death Discovery. 2021; 7: 193.","DOI":"10.1038\/s41420-021-00579-w"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Li K, Fan C, Chen J, Xu X, Lu C, Shao H, et al. Role of oxidative stress-induced ferroptosis in cancer therapy. Journal of Cellular and Molecular Medicine. 2024; 28: e18399.","DOI":"10.1111\/jcmm.18399"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Wu Y, Yu C, Luo M, Cen C, Qiu J, Zhang S, et al. Ferroptosis in Cancer Treatment: Another Way to Rome. Frontiers in Oncology. 2020; 10: 571127.","DOI":"10.3389\/fonc.2020.571127"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Cao JY, Dixon SJ. Mechanisms of ferroptosis. Cellular and Molecular Life Sciences. 2016; 73: 2195\u20132209.","DOI":"10.1007\/s00018-016-2194-1"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Zhou Q, Meng Y, Li D, Yao L, Le J, Liu Y, et al. Ferroptosis in cancer: From molecular mechanisms to therapeutic strategies. Signal Transduction and Targeted Therapy. 2024; 9: 55.","DOI":"10.1038\/s41392-024-01769-5"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Dixon SJ, Stockwell BR. The Hallmarks of Ferroptosis. Annual Review of Cancer Biology. 2019; 3: 35\u201354.","DOI":"10.1146\/annurev-cancerbio-030518-055844"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Szulc A, Wo\u017aniak M. Targeting Ferroptosis as the Achilles\u2019 Heel of Breast Cancer: Mechanisms and Therapeutic Opportunities from a Comprehensive Systematic Review. International Journal of Molecular Sciences. 2025; 26: 9902.","DOI":"10.3390\/ijms26209902"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Romo B, Fuentes Z, Randolph L, Mahajan M, Aller EJ, Ebrahimi B, et al. Targeting the Leukemia Inhibitory Factor\/Leukemia Inhibitory Factor Receptor Axis Reduces the Growth of Inflammatory Breast Cancer by Promoting Ferroptosis. Cancers. 2025; 17: 790.","DOI":"10.3390\/cancers17050790"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Li Z, Chen L, Chen C, Zhou Y, Hu D, Yang J, et al. Targeting ferroptosis in breast cancer. Biomarker Research. 2020; 8: 58.","DOI":"10.1186\/s40364-020-00230-3"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Sui S, Xu S, Pang D. Emerging role of ferroptosis in breast cancer: New dawn for overcoming tumor progression. Pharmacology & Therapeutics. 2022; 232: 107992.","DOI":"10.1016\/j.pharmthera.2021.107992"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Glibetic N, Weichhaus M. Metabolic Regulation of Ferroptosis in Breast Cancer. International Journal of Molecular Sciences. 2025; 26: 9686.","DOI":"10.3390\/ijms26199686"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Chen F, Kang R, Liu J, Tang D. The ACSL4 Network Regulates Cell Death and Autophagy in Diseases. Biology. 2023; 12: 864.","DOI":"10.3390\/biology12060864"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Huang Q, Ru Y, Luo Y, Luo X, Liu D, Ma Y, et al. Identification of a targeted ACSL4 inhibitor to treat ferroptosis-related diseases. Science Advances. 2024; 10: eadk1200.","DOI":"10.1126\/sciadv.adk1200"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Obeagu EI, Maibouge Tanko MS. Iron metabolism in breast cancer: mechanisms and therapeutic implications: a narrative review. Annals of Medicine and Surgery. 2025; 87: 3403\u20133409.","DOI":"10.1097\/MS9.0000000000003173"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Chen X, Li J, Kang R, Klionsky DJ, Tang D. Ferroptosis: machinery and regulation. Autophagy. 2021; 17: 2054\u20132081.","DOI":"10.1080\/15548627.2020.1810918"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Corazzari M, Collavin L. Wild-type and mutant p53 in cancer-related ferroptosis. A matter of stress management? Frontiers in Genetics. 2023; 14: 1148192.","DOI":"10.3389\/fgene.2023.1148192"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Lee S, Hwang N, Seok BG, Lee S, Lee SJ, Chung SW. Autophagy mediates an amplification loop during ferroptosis. Cell Death & Disease. 2023; 14: 464.","DOI":"10.1038\/s41419-023-05978-8"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Kang R, Kroemer G, Tang D. The tumor suppressor protein p53 and the ferroptosis network. Free Radical Biology & Medicine. 2019; 133: 162\u2013168.","DOI":"10.1016\/j.freeradbiomed.2018.05.074"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Yang J, Wang Y, Liu F, Zhang Y, Han F. Crosstalk between ferroptosis and endoplasmic reticulum stress: A potential target for ovarian cancer therapy (Review). International Journal of Molecular Medicine. 2025; 55: 97.","DOI":"10.3892\/ijmm.2025.5538"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Lee YS, Lee DH, Choudry HA, Bartlett DL, Lee YJ. Ferroptosis-Induced Endoplasmic Reticulum Stress: Cross-talk between Ferroptosis and Apoptosis. Molecular Cancer Research. 2018; 16: 1073\u20131076.","DOI":"10.1158\/1541-7786.MCR-18-0055"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Eskander G, Abdelhamid SG, Wahdan SA, Radwan SM. Insights on the crosstalk among different cell death mechanisms. Cell Death Discovery. 2025; 11: 56.","DOI":"10.1038\/s41420-025-02328-9"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Man M, Pang Z, Dang J, Chen B, Chen G, Zeng X. Ferroptosis-related differential gene expression and immune correlates in luminal a subtype breast cancer: a prognostic model approach. World Journal of Surgical Oncology. 2025; 23: 410.","DOI":"10.1186\/s12957-025-04059-8"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Cao J, Zhou T, Wu T, Lin R, Huang J, Shi D, et al. Targeting estrogen-regulated system xc\u2013 promotes ferroptosis and endocrine sensitivity of ER+ breast cancer. Cell Death & Disease. 2025; 16: 30.","DOI":"10.1038\/s41419-025-07354-0"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Cui Y, Li Y, Xu Y, Liu X, Kang X, Zhu J, et al. SLC7A11 protects luminal A breast cancer cells against ferroptosis induced by CDK4\/6 inhibitors. Redox Biology. 2024; 76: 103304.","DOI":"10.1016\/j.redox.2024.103304"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Liu J, Tang R, Zheng J, Luo K. Targeting ferroptosis reveals a new strategy for breast cancer treatment: a bibliometric study. Discover Oncology. 2024; 15: 679.","DOI":"10.1007\/s12672-024-01569-x"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Shi JY, Che X, Wen R, Hou SJ, Xi YJ, Feng YQ, et al. Ferroptosis biomarkers predict tumor mutation burden\u2019s impact on prognosis in HER2-positive breast cancer. World Journal of Clinical Oncology. 2024; 15: 391\u2013410.","DOI":"10.5306\/wjco.v15.i3.391"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Hua Y, Duan N, Sun C, Yang F, Tian M, Sun Y, et al. Targeting SLC7A11-mediated cysteine metabolism for the treatment of trastuzumab-resistant HER2-positive breast cancer. eLife. 2025; 14: RP103953.","DOI":"10.7554\/eLife.103953"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Hu L, Hu J, Qin C, Liu S, Yu Y. Ferroptosis in TNBC: interplay with tumor-infiltrating immune cells and therapeutic implications. Molecular and Cellular Biochemistry. 2025; 480: 5029\u20135039.","DOI":"10.1007\/s11010-025-05305-z"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Zhang K, Guo L, Li X, Hu Y, Luo N. Cancer-associated fibroblasts promote doxorubicin resistance in triple-negative breast cancer through enhancing ZFP64 histone lactylation to regulate ferroptosis. Journal of Translational Medicine. 2025; 23: 247.","DOI":"10.1186\/s12967-025-06246-3"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Antmen SE, Yalaza C, Tuncel F, Berkesoglu M, Erturk SE, Canacankatan N. Triple-negative breast cancer and ferroptosis: expression profiling of key regulatory genes. Archives of Medical Science. 2025; 21: 2079\u20132087.","DOI":"10.5114\/aoms\/208615"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Saha T, Lukong KE. Breast Cancer Stem-Like Cells in Drug Resistance: A Review of Mechanisms and Novel Therapeutic Strategies to Overcome Drug Resistance. Frontiers in Oncology. 2022; 12: 856974.","DOI":"10.3389\/fonc.2022.856974"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Lee H, Kim B, Park J, Park S, Yoo G, Yum S, et al. Cancer stem cells: landscape, challenges and emerging therapeutic innovations. Signal Transduction and Targeted Therapy. 2025; 10: 248.","DOI":"10.1038\/s41392-025-02360-2"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Bellala RS, Chittineedi P, Llaguno SNS, Mosquera JAN, Mohiddin GJ, Pandrangi SL. Down-Regulation of Cysteine-Glutamate Antiporter in ALDH1A1 Expressing Oral and Breast Cancer Stem Cells Induced Oxidative Stress-Triggered Ferroptosis. Journal of Cancer. 2024; 15: 6160\u20136176.","DOI":"10.7150\/jca.89429"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Kandettu A, Ghosal J, Tharayil JS, Kuthethur R, Mallya S, Narasimhamurthy RK, et al. Inhibition of mitochondrial genome-encoded mitomiR-3 contributes to ZEB1 mediated GPX4 downregulation and pro-ferroptotic lipid metabolism to induce ferroptosis in breast cancer cells. Free Radical Biology & Medicine. 2025; 234: 151\u2013168.","DOI":"10.1016\/j.freeradbiomed.2025.04.019"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Kumar S, Ziegler Y, Plotner BN, Flatt KM, Kim SH, Katzenellenbogen JA, et al. Resistance to FOXM1 inhibitors in breast cancer is accompanied by impeding ferroptosis and apoptotic cell death. Breast Cancer Research and Treatment. 2024; 208: 307\u2013320.","DOI":"10.1007\/s10549-024-07420-9"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Chittineedi P, Mohammed A, Abdul Razab MKA, Mat Nawi N, Pandrangi SL. Polyherbal formulation conjugated to gold nanoparticles induced ferroptosis in drug-resistant breast cancer stem cells through ferritin degradation. Frontiers in Pharmacology. 2023; 14: 1134758.","DOI":"10.3389\/fphar.2023.1134758"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Wu K, Zhang W, Chen H, Wu J, Wang X, Yang X, et al. An iron oxyhydroxide-based nanosystem sensitizes ferroptosis by a \u201dThree-Pronged\u201d strategy in breast cancer stem cells. Acta Biomaterialia. 2023; 160: 281\u2013296.","DOI":"10.1016\/j.actbio.2023.02.015"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"Fan C, Wu H, Du X, Li C, Zeng W, Qu L, et al. Inhibition of lysosomal TRPML1 channel eliminates breast cancer stem cells by triggering ferroptosis. Cell Death Discovery. 2024; 10: 256.","DOI":"10.1038\/s41420-024-02026-y"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"Yang X, Liang B, Zhang L, Zhang M, Ma M, Qing L, et al. Ursolic acid inhibits the proliferation of triple negative breast cancer stem like cells through NRF2 mediated ferroptosis. Oncology Reports. 2024; 52: 94.","DOI":"10.3892\/or.2024.8753"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"Luo M, Bao L, Xue Y, Zhu M, Kumar A, Xing C, et al. ZMYND8 protects breast cancer stem cells against oxidative stress and ferroptosis through activation of NRF2. The Journal of Clinical Investigation. 2024; 134: e171166.","DOI":"10.1172\/JCI171166"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"Yang Y, Lu Y, Zhang C, Guo Q, Zhang W, Wang T, et al. Phenazine derivatives attenuate the stemness of breast cancer cells through triggering ferroptosis. Cellular and Molecular Life Sciences. 2022; 79: 360.","DOI":"10.1007\/s00018-022-04384-1"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"Simsek D, Hassan GS, Sotgia F, Lisanti MP. Investigating the Role of Peroxisomes in Regulating Breast Cancer Stem Cell Mechanisms. International Journal of Molecular Sciences. 2025; 26: 11389.","DOI":"10.3390\/ijms262311389"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"Ye L, Zhu J, Wang X, Chen N, Sun Y, Zeng X, et al. Targeting cancer stem-like cells via cholesterol modulation and ferroptosis induction using a multifunctional nanoplatform to overcome drug resistance. Journal of Nanobiotechnology. 2025; 23: 722.","DOI":"10.1186\/s12951-025-03796-y"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"Malla R, Kundrapu DB, Bhamidipati P, Nagaraju GP, Muniraj N. Unleashing the Power of Yes-Associated Protein in Ferroptosis and Drug Resistance in Breast Cancer, with a Special Focus on Therapeutic Strategies. Cancers. 2023; 15: 5728.","DOI":"10.3390\/cancers15245728"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"Liu W, Luo G. CAV1 inhibits Xc\u2013 system through IFNGR1 to promote ferroptosis to inhibit stemness and improves anti-PD-1 efficacy in breast cancer. Translational Oncology. 2024; 50: 102149.","DOI":"10.1016\/j.tranon.2024.102149"},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"Cosialls E, Pacreau E, Duruel C, Ceccacci S, Elhage R, Desterke C, et al. mTOR inhibition suppresses salinomycin-induced ferroptosis in breast cancer stem cells by ironing out mitochondrial dysfunctions. Cell Death & Disease. 2023; 14: 744.","DOI":"10.1038\/s41419-023-06262-5"},{"key":"ref66","doi-asserted-by":"publisher","unstructured":"Zhang C, Xu S, Yin C, Hu S, Liu P. The role of the mTOR pathway in breast cancer stem cells (BCSCs): mechanisms and therapeutic potentials. Stem Cell Research & Therapy. 2025; 16: 156.","DOI":"10.1186\/s13287-025-04218-4"},{"key":"ref67","doi-asserted-by":"publisher","unstructured":"Xie Y, Wang B, Zhao Y, Tao Z, Wang Y, Chen G, et al. Mammary adipocytes protect triple-negative breast cancer cells from ferroptosis. Journal of Hematology & Oncology. 2022; 15: 72.","DOI":"10.1186\/s13045-022-01297-1"},{"key":"ref68","doi-asserted-by":"publisher","unstructured":"Bi Q, Sun ZJ, Wu JY, Wang W. Ferroptosis-Mediated Formation of Tumor-Promoting Immune Microenvironment. Frontiers in Oncology. 2022; 12: 868639.","DOI":"10.3389\/fonc.2022.868639"},{"key":"ref69","doi-asserted-by":"publisher","unstructured":"Tang D, Chen X, Kang R, Kroemer G. Ferroptosis: molecular mechanisms and health implications. Cell Research. 2021; 31: 107\u2013125.","DOI":"10.1038\/s41422-020-00441-1"},{"key":"ref70","doi-asserted-by":"publisher","unstructured":"Qi X, Wan Z, Jiang B, Ouyang Y, Feng W, Zhu H, et al. Inducing ferroptosis has the potential to overcome therapy resistance in breast cancer. Frontiers in Immunology. 2022; 13: 1038225.","DOI":"10.3389\/fimmu.2022.1038225"},{"key":"ref71","doi-asserted-by":"publisher","unstructured":"Jang N, Kim IK, Jung D, Chung Y, Kang YP. Regulation of Ferroptosis in Cancer and Immune Cells. Immune Network. 2025; 25: e6.","DOI":"10.4110\/in.2025.25.e6"},{"key":"ref72","doi-asserted-by":"publisher","unstructured":"Desterke C, Xiang Y, Elhage R, Duruel C, Chang Y, Hama\u00ef A. Ferroptosis Inducers Upregulate PD-L1 in Recurrent Triple-Negative Breast Cancer. Cancers. 2023; 16: 155.","DOI":"10.3390\/cancers16010155"},{"key":"ref73","doi-asserted-by":"publisher","unstructured":"Xu Y, Ge M, Xu Y, Yin K. Ferroptosis: a novel perspective on tumor immunotherapy. Frontiers in Immunology. 2025; 16: 1524711.","DOI":"10.3389\/fimmu.2025.1524711"},{"key":"ref74","doi-asserted-by":"publisher","unstructured":"Gao J, Zhang X, Liu Y, Gu X. Ferroptosis in immune cells: Implications for tumor immunity and cancer therapy. Cytokine & Growth Factor Reviews. 2025; 84: 59\u201373.","DOI":"10.1016\/j.cytogfr.2025.06.007"},{"key":"ref75","doi-asserted-by":"publisher","unstructured":"Lin Z, Zou S, Wen K. The crosstalk of CD8+ T cells and ferroptosis in cancer. Frontiers in Immunology. 2024; 14: 1255443.","DOI":"10.3389\/fimmu.2023.1255443"},{"key":"ref76","doi-asserted-by":"publisher","unstructured":"Morgan PK, Pernes G, Huynh K, Giles C, Paul S, Smith AAT, et al. A lipid atlas of human and mouse immune cells provides insights into ferroptosis susceptibility. Nature Cell Biology. 2024; 26: 645\u2013659.","DOI":"10.1038\/s41556-024-01377-z"},{"key":"ref77","doi-asserted-by":"publisher","unstructured":"Shang D, Zheng L, Chen J, Tan T, Yao M, Wu H, et al. Ferroptosis: A new horizon in cancer therapy. Chinese Medical Journal. 2025; 138: 3351\u20133380.","DOI":"10.1097\/CM9.0000000000003915"},{"key":"ref78","doi-asserted-by":"publisher","unstructured":"Zhong J, Shen X, Zhou J, Yu H, Wang B, Sun J, et al. Development and validation of a combined hypoxia and ferroptosis prognostic signature for breast cancer. Frontiers in Oncology. 2023; 13: 1077342.","DOI":"10.3389\/fonc.2023.1077342"},{"key":"ref79","doi-asserted-by":"publisher","unstructured":"Wei G, Liu J, Lan J, Ji G, Xia H, Zhao Z, et al. Targeting hypoxia-induced CBS expression inhibits breast cancer stem cells through the induction of ferroptosis. Genes & Diseases. 2023; 10: 2195\u20132198.","DOI":"10.1016\/j.gendis.2023.02.034"},{"key":"ref80","doi-asserted-by":"publisher","unstructured":"Chen X, Kang R, Kroemer G, Tang D. Broadening horizons: the role of ferroptosis in cancer. Nature Reviews. Clinical Oncology. 2021; 18: 280\u2013296.","DOI":"10.1038\/s41571-020-00462-0"},{"key":"ref81","doi-asserted-by":"publisher","unstructured":"Su J, Zhao Q, Zheng Z, Wang H, Bian C, Meng L, et al. Prospective Application of Ferroptosis in Hypoxic Cells for Tumor Radiotherapy. Antioxidants. 2022; 11: 921.","DOI":"10.3390\/antiox11050921"},{"key":"ref82","doi-asserted-by":"publisher","unstructured":"Liu Y, Lu S, Wu LL, Yang L, Yang L, Wang J. The diversified role of mitochondria in ferroptosis in cancer. Cell Death & Disease. 2023; 14: 519.","DOI":"10.1038\/s41419-023-06045-y"},{"key":"ref83","doi-asserted-by":"publisher","unstructured":"Gan H, Huang X, Luo X, Li J, Mo B, Cheng L, et al. A Mitochondria-Targeted Ferroptosis Inducer Activated by Glutathione-Responsive Imaging and Depletion for Triple Negative Breast Cancer Theranostics. Advanced Healthcare Materials. 2023; 12: e2300220.","DOI":"10.1002\/adhm.202300220"},{"key":"ref84","doi-asserted-by":"publisher","unstructured":"Li J, He D, Li S, Xiao J, Zhu Z. Ferroptosis: the emerging player in remodeling triple-negative breast cancer. Frontiers in Immunology. 2023; 14: 1284057.","DOI":"10.3389\/fimmu.2023.1284057"},{"key":"ref85","doi-asserted-by":"publisher","unstructured":"Riaz T, Saleem MA, Khan MUM, Rashid MAR, Zubair M. Ferroptosis as a Therapeutic Avenue in Triple-Negative Breast Cancer: Mechanistic Insights and Prognostic Potential. Biomedicines. 2025; 13: 2037.","DOI":"10.3390\/biomedicines13082037"},{"key":"ref86","doi-asserted-by":"publisher","unstructured":"Peng C, Chen Y, Jiang M. Targeting ferroptosis: a promising strategy to overcome drug resistance in breast cancer. Frontiers in Oncology. 2024; 14: 1499125.","DOI":"10.3389\/fonc.2024.1499125"},{"key":"ref87","doi-asserted-by":"publisher","unstructured":"Ji G, Yuan W, Wang X, Li W, Sun Z, Wei Z, et al. 5-Fluorouracil induces ferroptosis in breast cancer cells via targeting SLC7A11. Biochemical and Biophysical Research Communications. 2025; 770: 151972.","DOI":"10.1016\/j.bbrc.2025.151972"},{"key":"ref88","doi-asserted-by":"publisher","unstructured":"Zhang Y, Han X, Long R, Wu Z, Qi X. Advances and therapeutic potential of ferritin-involved drug delivery systems for ferroptosis-targeted therapy. Biomaterials Science. 2026; 14: 100\u2013121.","DOI":"10.1039\/d5bm01369k"},{"key":"ref89","doi-asserted-by":"publisher","unstructured":"Gao J, Ye T, Miao H, Liu M, Wen L, Tian Y, et al. Antibody-functionalized iron-based nanoplatform for ferroptosis-augmented targeted therapy of HER2-positive breast cancer. Bioactive Materials. 2025; 52: 702\u2013718.","DOI":"10.1016\/j.bioactmat.2025.06.034"},{"key":"ref90","doi-asserted-by":"publisher","unstructured":"Lorito N, Subbiani A, Smiriglia A, Bacci M, Bonechi F, Tronci L, et al. FADS1\/2 control lipid metabolism and ferroptosis susceptibility in triple-negative breast cancer. EMBO Molecular Medicine. 2024; 16: 1533\u20131559.","DOI":"10.1038\/s44321-024-00090-6"},{"key":"ref91","doi-asserted-by":"publisher","unstructured":"Zhang H, Yang F, Xiao Y, Jiang Y, Shao Z. Conceptualizing the complexity of ferroptosis to treat triple-negative breast cancer: theory-to-practice. Cancer Biology & Medicine. 2023; 20: 98\u2013103.","DOI":"10.20892\/j.issn.2095-3941.2022.0767"},{"key":"ref92","doi-asserted-by":"publisher","unstructured":"Tan LK, Liu J, Ma CZ, Huang S, He FH, Long Y, et al. Iron-Dependent Cell Death: Exploring Ferroptosis as a Unique Target in Triple-Negative Breast Cancer Management. Cancer Management and Research. 2025; 17: 625\u2013637.","DOI":"10.2147\/CMAR.S503932"},{"key":"ref93","doi-asserted-by":"publisher","unstructured":"Huang G, Cai Y, Ren M, Zhang X, Fu Y, Cheng R, et al. Salidroside sensitizes Triple-negative breast cancer to ferroptosis by SCD1-mediated lipogenesis and NCOA4-mediated ferritinophagy. Journal of Advanced Research. 2025; 74: 589\u2013607.","DOI":"10.1016\/j.jare.2024.09.027"},{"key":"ref94","doi-asserted-by":"publisher","unstructured":"Mu Y, Fan Y, He L, Hu N, Xue H, Guan X, et al. Enhanced cancer immunotherapy through synergistic ferroptosis and immune checkpoint blockade using cell membrane-coated nanoparticles. Cancer Nanotechnology. 2023; 14: 83.","DOI":"10.1186\/s12645-023-00234-2"},{"key":"ref95","doi-asserted-by":"publisher","unstructured":"Wang Q, Van Alsten SC, Ji X, Salim E, Salazar N, Scott JE, et al. Molecular and socioeconomic characteristics of inflammatory breast cancer in the Carolina Breast Cancer Study. Breast Cancer Research and Treatment. 2026; 215: 61.","DOI":"10.1007\/s10549-025-07884-3"},{"key":"ref96","doi-asserted-by":"publisher","unstructured":"Wu X, Sheng H, Zhao L, Jiang M, Lou H, Miao Y, et al. Co-loaded lapatinib\/PAB by ferritin nanoparticles eliminated ECM-detached cluster cells via modulating EGFR in triple-negative breast cancer. Cell Death & Disease. 2022; 13: 557.","DOI":"10.1038\/s41419-022-05007-0"},{"key":"ref97","doi-asserted-by":"publisher","unstructured":"Wu C, Zhang F, Li B, Li Z, Xie X, Huang Y, et al. A Self-Assembly Nano-Prodrug for Combination Therapy in Triple-Negative Breast Cancer Stem Cells. Small. 2023; 19: e2301600.","DOI":"10.1002\/smll.202301600"},{"key":"ref98","doi-asserted-by":"publisher","unstructured":"Zhou L, Wu Z, Luo K, Zheng H, Tian Y, Pan Q, et al. Polysaccharides from Huaier induce autophagy-dependent ferroptosis to inhibit breast cancer stem cells in triple-negative breast cancer. Cancer Cell International. 2025; 26: 13.","DOI":"10.1186\/s12935-025-04102-4"}],"container-title":["Frontiers in Bioscience-Landmark"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/31\/4\/10.31083\/FBL50950","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T09:31:28Z","timestamp":1777455088000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/31\/4\/10.31083\/FBL50950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":98,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"alternative-id":["S2768-6701(26)02081-2"],"URL":"https:\/\/doi.org\/10.31083\/fbl50950","relation":{},"ISSN":["2768-6701","2768-6698"],"issn-type":[{"value":"2768-6701","type":"print"},{"value":"2768-6698","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"article-number":"50950"}}